Replies to post #18321 on Biotech Values

[DewDiligence]

>DNDN - As a CFO myself, I find it hard to believe that replacing their head of operations with their CFO, "Best Positions" a company that supposedly is on the verge of a manufacturing buildout! Just my opinion!<

Duly noted. What’s your current sentiment? T.i.a.

p.s. As a professional CFO do you have any opinion on the proposed FASB rule changes for reporting pension deficits and shortfalls?

[poorgradstudent]

>DNDN - As a CFO myself, I find it hard to believe that replacing their head of operations with their CFO, "Best Positions" a company that supposedly is on the verge of a manufacturing buildout..! <

I think that statement is just boilerplate CEO bs. Rather than say nothing, most CEOs feel inclined to make everything sound positive. In other words, if "This realignment best positions the company as we build-out our manufacturing facilities and prepare for the commercialization of PROVENGE", then why wasn't it done a long time ago?


===


As an aside, I think it would be interesting to add another nugget of information to our clinical trials calendar. To add announcements of upper management changes for companies:

1) without an approved product that are currently running pivotal phase III trials, or

2) have announced their intention to file a BLA and have disclosed all the data that form the basis of the application.


Just a small entry, something like "CEO left Oct 2005(!)". I think it would be interesting to see if we can draw any type of correlation between upper management departures and phase III / NDA / BLA success. Rather than discuss departure motives that are often impossible to verify, we could at least have some empirical data to observe a general trend, if one exists.

For example, OSIP had no turnover leading up to the successful phase III results or the approval of Tarceva.

MLNM, on the other hand, had two people from management leave. One, kenneth starr, to spend more time with family and the other, maraganore, to become CEO for another company (alnylam). Starr's departure was of the fishy-variety.

So that's one for, one against. A few more data points may help! :-)